MFS Medifocus Inc

Medifocus Inc. (Medifocus or the Company) (TSX VENTURE:MFS)(OTCQX:MDFZF) has
agreed, subject to regulatory approval, to issue an aggregate of 1,090,000
common shares at a deemed price of $0.25 per common share to settle an aggregate
of $272,500 of debt representing unpaid salary ($210,000) and amounts due to
service providers ($62,500). 


All of the common shares issued in connection with the shares for debt
transaction will subject to a 4-month and one day hold period from the date of
issuance.


About Medifocus 

Medifocus owns a patented microwave focusing technology platform (the Adaptive
Phased Array (APA) technology), which can precisely target and control microwave
energy to cause heating in cancerous tumors anywhere in the body reliably and
repeatedly. The ability to target tumors with a precision controlled dose of
heat can be used to destroy tumors at higher temperatures, to treat tumors in
combination with chemotherapy and/or radiation at moderate temperatures for
increased effectiveness and reduced toxicity and to trigger the targeted release
of therapeutic drugs and genes at tumor sites at lower temperatures. While the
core technology has been licensed from the Massachusetts Institute of
Technology, Medifocus has further refined the precision of the microwave
focusing and control ability and developed a commercial system dedicated
exclusively for the treatment of Breast Cancer. With the acquisition of
Prolieve(R), Medifocus now owns in addition, a revenue generating commercial BPH
heat treatment product generating cash flow to support the development and
commercialization of other catheter based or APA based external focused heat
systems for targeted thermotherapy of deep seated tumors anywhere in the body.
Please visit www.medifocusinc.com for more details.


Forward-Looking Statements and Information 

This news release contains forward-looking statements, which may not be based on
historical facts. Such forward-looking statements involve known and unknown
risks, uncertainties and other factors that may cause the actual results events
or developments to be materially different from any future results, events or
developments expressed or implied by such forward-looking statements. These
factors should be considered carefully and readers are cautioned not to place
undue reliance on such forward-looking statements. Except as required under
applicable securities laws, the Company disclaims any obligation to update any
such factors or to publicly announce the results of any revisions to any of the
forward-looking statements contained herein to reflect future results, events or
developments. 


FOR FURTHER INFORMATION PLEASE CONTACT: 
Medifocus Inc.
John Mon
(410) 290-5734
jmon@medifocususa.com
www.medifocusinc.com

Medifocus (TSXV:MFS)
Historical Stock Chart
From Jun 2024 to Jul 2024

Medifocus (TSXV:MFS)
Historical Stock Chart
From Jul 2023 to Jul 2024